The Group's principal activity is to develop and market products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. It operates in two segments: the Biologic Drug Candidates and the Biologic Tissue Product. The Biologic Drug Candidates segment focuses on clinical trials and discovery efforts to identify additional medical indications. Biologic Tissue Product segment includes the manufacture and sale of Osteocel. It operates in the United States.
Alacra Alerts:
Receive alerts on the latest reports on Osiris Therapeutics, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
